|
PolyHemeŽ Trauma Trial Information Page |
| Research Project Title: |
A Phase III, Randomized, Controlled, Open-Label
Multicenter,
Parallel Group Study Using Provisions for Exception from Informed
Consent
Requirements Designed to Evaluate the Safety and Efficacy of Poly SFH-P
Injection
[Polymerized Human Hemoglobin (Pyridoxylated) PolyHemeŽ] When Used to
Treat
Patients in Hemorrhagic Shock Following Traumatic Injuries Beginning in
the
Prehospital Setting. |
| Study Purpose: |
To evaluate the life-saving potential of
PolyHemeŽ
when given to severely injured and bleeding patients, starting at the
scene
of injury. |
| Principal Investigator: |
David Hoyt, M.D. Professor of Surgery Director, UCSD Healthcare Trauma Unit |
| Study Sponsor: |
Northfield
Laboratories Inc. |
UCSD and Scripps Mercy Hospital researchers are proposing to do this clinical study using an "Exception from Informed Consent" under federal regulation 21 CFR 50.24: This regulation allows research to procede without obtaining the consent of the research subject when: